A trailblazing pioneer, Affymetrix (AFFX) got off largely under-the-radar in 1992, and came public with its IPO in June 1996.
AFFX "blasted-off" like a rocket in the early 2000s (with over a 1500% Total Return), as it developed its DNA Chip Technology ("biochips") and integrated products, and was on the leading edge in preparing and positioning itself for The Human Genome Project, the worldwide project that completed sequencing the human gene and DNA (deoxyribonucleic acid). This led to the ongoing boom in biotechnology, big-pharma inroads, and R&D generally, and advancements in learning, as well as exponential leaps in medicine have continuously been made.
Having been professionally engaged in a career in the medicine/ healthcare field most of my...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: